gemigliptin + irbesartan

Gemigliptin + irbesartan is a **combination of two small molecule drugs** used together, primarily evaluated in clinical pharmacokinetic studies. Gemigliptin is a oral, potent, selective, reversible, and competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), indicated for type 2 diabetes mellitus to improve glycemic control and protect pancreatic beta-cell function by increasing incretin (GLP-1) levels, enhancing insulin secretion, and reducing glucagon secretion[6][7][9]. Irbesartan is an oral angiotensin II receptor antagonist (ARB) used mainly for hypertension and diabetic nephropathy, acting by blocking the AT1 receptor, leading to vascular smooth muscle relaxation and decreased secretion of aldosterone, thus lowering blood pressure[2][4][8]. Pharmacokinetic interaction studies show that concomitant use does not affect the PK properties of either drug, and no dose adjustments are necessary for gemigliptin when co-administered with irbesartan[1][3][5]. The combination has primarily been investigated for safety, tolerability, and pharmacokinetic properties in healthy volunteers and may be considered in patients needing dual management of diabetes and hypertension.

Other names

gemigliptin + irbesartan